

CURRICULUM VITAE
YIHONG WANG, M.D., Ph.D.

Business Address	Department of Pathology, Rhode Island Hospital 593 Eddy Street, Providence, RI 02903
Business Telephone	(401) 444-9897
Fax Number	(401) 444-8514
E-mail Address	ywang6@ Lifespan.org

EDUCATION

Medical School	College of Medicine, Shandong University, Jinan, China M.D., 1994
Other Advanced Degrees	College of Arts and Sciences, Ohio University, Athens, OH Ph.D., 2000

POST GRADUATE TRAINING

Internship	Shandong Medical University/Qi Lu Hospital Jinan, Shandong, China, 1993-1994
Postdoctoral Fellow	St. Elizabeth's Hospital, Tufts University School of Medicine Boston, MA, 2000-2001 BIDMC Genomics Center Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA, 2002-2004
Residency	Anatomic and Clinical Pathology Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA 2004-2008
Fellowship	Breast Pathology Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA, 2008-2009

POSTGRADUATE HONORS AND AWARDS

Excellent Student Award	Shandong Medical University, Jinan, China, 1990-1994
MBL Research Award	Marine Biology Laboratory Woods Hole, MA supported by Howard Hughes Medical Institute, 1997
Graduate Student Travel Award	College of Arts and Sciences Ohio University, Athens, OH, 1998-2000
First place prize	Deregulated IL-6 gene expression in prostate cancer: A target for therapeutic intervention. Zerbini, L., Wang, Y. Libermann, T.

Dana-Farber/Harvard Cancer Center (DF/HCC) SPORE
Symposium, Newport, RI, 2003

Junior Member Abstract Award College of American Pathologists (CAP)'06 Annual Meeting, 2006

Best Abstract Award International Association of the Chinese Pathologists (IACP)
USCAP 2008 Annual Meeting, 2008

Honored Resident Harvard Medical School Retreat, Cape Cod, 2008

AACR Scholar Travel Award Susan G Komen and AACR Scholar in Training Award, 31st Annual CTSC
-AACR San Antonio Breast Cancer Symposium (SABCS), 2008

Stowell-Orbison Certificates of Merit USCAP 2009 Annual Meeting, 2009

Certificate of Recognition for Exemplary Teaching Warren Alpert Medical School of Brown University
BIOL 3643 IMS I: Histology; 2013-14; 2016-17

PROFESSIONAL LICENSES AND BOARD CERTIFICATION

Medical License State of Massachusetts, 2004-2009

State of New York, 2009-2012

Rhode Island License, 2012-present

Certification Diplomate of the American Board of Pathology in Anatomic Pathology,
2009 – 2019

College of American Pathologist (CAP) certified Breast Pathologist (MBP
Advanced Practical Pathology Program) 2012- 2022

ACADEMIC APPOINTMENTS

Research/Teaching Assistant Chinese Academy of Medical Science and Peking Union Medical College,
Beijing, China, 1994–1996

Teaching Assistant College of Arts and Sciences and College of Osteopathic Medicine,
Ohio University, Athens, 1996-2000

Assistant Professor Department of Pathology & Laboratory Medicine
Montefiore Medical Center/Albert Einstein College of Medicine
Bronx, NY 2009 – 2012

Assistant Professor Department of Pathology & Laboratory Medicine
Lifespan Medical Center/Warren Alpert Medical School of Brown
University, Providence, RI, 2012 – 2017

Associate Professor Department of Pathology & Laboratory Medicine
Lifespan Medical Center/Warren Alpert Medical School of Brown
University, Providence, RI, 2017- present

HOSPITAL APPOINTMENTS

Attending Pathologist Department of Pathology & Laboratory Medicine
Montefiore Medical Center/Albert Einstein College of Medicine
Bronx, NY 2009 – 2012

Attending Pathologist Department of Pathology & Laboratory Medicine
Lifespan Medical Center/Warren Alpert Medical School of Brown
University, Providence, RI, 2012 - present

OTHER APPOINTMENTS

NATIONAL COMMITTEES

Member United States & Canadian Academy of Pathology (USCAP)
Abstract Review Board for Breast Pathology, 2015 – 2018

Member International Breast Tumor Infiltrating Lymphocytes (TILs) Study Group
2015 – Present

UNIVERSITY AND HOSPITAL COMMITTEES

Member NAPBC Breast Steering Committee, The comprehensive Cancer Center
2012 – Present

Member Breast Steering Committee, Rhode Island Hospital, 2012 - present

Member Surgical Fellowship Program
Rhode Island Hospital, RI, 2012-present

Member Gastrointestinal Fellowship Program
Rhode Island Hospital, RI, 2012-present

Member Educational Committee of Surgical Pathology in Department of Pathology,
Montefiore Medical Center, NY, 2009-2012

Core Member Women's Health Fellowship Program
Montefiore Medical Center, NY, 2009-2012

SCIENTIFIC AND MEDICAL JOURNAL AD HOC REVIEWER

Annals of Surgical Oncology
BMC cancer
Breast Cancer Research (BRCR)
Clinical Cancer Research (CCR)
Clinics on Oncology
Histology and Histopathology
International Journal of Surgical Pathology (IJSP)
Journal of Biomedical Optics (JBO)
Journal of Breast Cancer: Targets and Therapy
Journal of Hematology and Oncology
Laboratory Investigation
Modern Pathology

Oncotarget
Tumor Biology
World Journal of Surgical Oncology (WJSO)

CLINICAL TRIALS

- Member Brown University Oncology Group (BrOUG) - Breast Cancer neoadjuvant Trial Study: BrUOG B313, 2015 – Present: “Neoadjuvant BYL719 + Weekly, Paclitaxel For Patients With ER+, HER2-, PIK3CA Mutated Breast Cancer: A Brown University Oncology Research Group Phase II Study”
- Member
Lead Pathologist M14-011: A Randomized, Placebo-Controlled, Double-Blind, Phase 3 Study Evaluating Safety and Efficacy of the Addition of Veliparib Plus Carboplatin Versus the Addition of Carboplatin to Standard Neoadjuvant Chemotherapy Versus Standard Neoadjuvant Chemotherapy in Subjects with Early Stage Triple Negative Breast Cancer (TNBC)
- Member NSABP-51/RTOG 1304 A Randomized Phase III Clinical Trial Evaluating Post-Mastectomy Chest Wall and Regional Nodal XRT and Post-Lumpectomy Regional Nodal XRT in Patients with Positive Axillary Nodes before Neoadjuvant Chemotherapy Who Convert to Pathological Negative Axillary Nodes after Neoadjuvant Chemotherapy
- Member
Lead Pathologist PRECISION (Profiling Breast Cancer For Radiotherapy Omission): A phase II study of breast conserving surgery without adjuvant radiation therapy for favorable-risk breast cancer

MEMBERSHIP IN SOCIETIES

- American Society of Cancer Research (AACR), 2000 – 2004, 2015 – present
- American Society of Cancer Research - Cancer Immunology Working Group (AACR-CIMM), 2016 – present
- College of American Pathologists (CAP), 2004- present
- Chinese American Pathology Association (CAPA), 2014 – present
- International Society for Breast Pathologists (ISBP), 2014 – present
- New England Society of Pathologists, 2004 – 2009
- New England Residents Society, 2004 – 2009
- Rhode Island Society of Pathologists (RISP), 2012 – present
- Society for Neuroscience (SfN), 1996 - 2000
- The New York Pathological Society, 2009- 2012
- United State & Canadian Academy of Pathology (USCAP), 2004 - present

GRANT AND PATENT

- 2002 – 2004 Developmental Project for the Prostate Cancer SPORE Grant
Deregulated IL-6 gene expression in prostate cancer: A target for therapeutic intervention.
(Libermann, T)
- 2002 Patent
An improvement in targeted apoptosis induction with transcriptional factor AP-1 and NF- κ B.
(Libermann, T, Zerbini, L, Wang, Y)
- 2004 – 2006 CapCure Grant
A novel rational treatment modality for advanced prostate cancer: combination
of anti-inflammatory therapy (Libermann, T)
- 2006 – 2008 BIDMC Department of Pathology Intra-Departmental Grant
Investigation of angiopoietin-like protein 4 as a potential marker for conventional
renal cell carcinoma (Wang, Y)
- 2009 – 2014 Study of the Relationship between R-cadherin and Breast Cancer
Progression (Hazan, R) NIH/NCI RO1 grant
- 2013 Patent
Human beta V-Tubulin Antibody and Methods of Use
(Horowitz, SB, Chao, S, Wang, Y, Verdier-Pinard, P, and McDaid H)
- 2010 – Present MicroRNA Expression Profiling of Benign Breast Tissue and Breast Cancer
Risk (Rohan, T) NIH grant
- 2017 Patent
Collagens as markers for breast cancer treatment
(Brodsky, AS, Wang, Y, Resnick, MR)
- 2017- Present Molecular markers of risk of subsequent invasive breast cancer in women with ductal
carcinoma in situ (Rohan, T), NIH grant

ORIGINAL PUBLICATIONS IN PEER-REVIEWED JOURNALS

1. Huang X, Zhang J, Yang X, **Wang Y**, Zhao H. Functional analysis of human A γ -globin gene promoter with 173 T \rightarrow C mutation. *ACTA Acad Med Sinicae* 1999, 21(4), 250-256.
2. **Wang Y**, Chen X, and Colvin RA. Expression of the Na⁺/Ca²⁺ exchange ameliorates ionomycin-induced cell death in PC12 cells. *Biochem Biophys Res Commun* 2000, 276, 93-96.
3. Zerbini LF, **Wang Y**, Cho J, and Libermann TA. Constitutive activation of nuclear factor κ B p50/p65 and fra-1 and junD is essential for deregulated interleukin 6 expression in prostate cancer. *Cancer Res* 2003, 63, 2206-15.
4. **Wang Y**, Pampou S, Fujikawa K, and Varticovski L. The opposite effect of Angiopoietin 1 and VEGF in vascular permeability. *J Cell Physiol* 2004, 198(1), 53-61
5. Cho J, Akbarali Y, Zerbini LF, Gu X, Boltax J, **Wang Y**, Oettgen P, Zhang D, and Libermann TA. Isoforms of the Ets transcription factor NERF/ELF2 physically interact with AML1 and mediate opposing effect on AML1 mediated transcription of B cell-specific blk gene. *J Biol Chem* 2004, 279 (19), 19512-22.

6. Zerbini LF, **Wang Y**, Czibere A, Correa R, Cho J, Ijiri K, Wei W, Joseph M, Gu X, Grall F, Goldring M, Zhou J, and Libermann TA. NF κ B-mediated repression of growth arrest- and DNA-damage-inducible proteins 45 α and γ is essential for cancer cell survival. *Proc Natl Acad Sci U S A* 2004, 101, 13618-23
7. Zerbini LF*, **Wang Y***, Czibere A, Correa R, Cho J and Libermann TA. Blockage of NF κ B-induces serine 15 phosphorylation of mutant p53 by JNK kinase in prostate cancer cells. *Cell Cycle* 2005, 4(9), 1247-53 *co-first authors
8. Zerbini LF, Czibere A, **Wang Y**, Correa R, Otu H, Joseph M, Takayasu Y, Silver M, Gu X, Ruchusatsawat K, Li L, Sarkar D, Zhou J, Fisher PB and Libermann TA. A novel pathway involving MDA-7/IL-24 mediated NSAID induced apoptosis and growth arrest of cancer cells. *Cancer Res* 2006, 66(24), 11922-31
9. Costa DB, Miksad RA, Buff MS, **Wang Y** and Dezube BJ. A case of fatal sickle cell intrahepatic cholestasis despite use of exchange transfusion in an African-American patient. *J Natl Med Assoc* 2006, 98 (7), 1183-7
10. **Wang Y**, Doucette S, Qian Q, Kirby J. Yield of primary and repeat induced sputum testing for *Pneumocystis jiroveci* detection in HIV positive and negative patients. *Arch Pathol Lab Med* 2007, 131, 1582-4
11. **Wang Y**, Beckwith B, Smith C, and Horowitz G. Misleading glycosylated hemoglobin results in a patient with hemoglobin SC disease. *Clin Chem* 2007, 53 (7) 1394-5
12. **Wang Y**, Kirby J and Qian Q. Effective use of JC virus PCR for diagnosis of progressive multifocal leucoencephalopathy. *J Med Microbiol*, 2009, 58, 253-5
13. Collins LC, **Wang Y**, Connolly JL, Baer H, Schnitt S, Colditz G and Tamimi RM. Potential role of tissue microarrays for the study of biomarker expression in benign breast disease and normal breast tissue. *Appl Immunohistochem Mol Morphol*, 2009, 17(5), 438-441
14. Zhou C, Cohen D, **Wang Y**, Lee H, Mondelblatt A, Tsai T, Aguirre A, Connolly J and Fujimoto J. Integrated Optical Coherence Tomography and microscopy for Ex-vivo Multi-scale Evaluation of Human Breast Pathology. *Cancer Res*, 2010, 70 (24), 10071-9.
15. Genega EM, Ghebremichael M, Najarian R, Fu Y, **Wang Y**, Argani P, Grisanzio C and Signoretti S. Carbonic Anhydrase IX expression in renal neoplasms: correlation with tumor type and grade. *Am J Clin Pathol*, 2010, 134 (6), 873-9
16. Tung N, **Wang Y**, Collins LC, Kaplan J, Li H, Gelman R, Comander AH, Gallagher B, Fettes K, Krag K, Stoeckert KA, Legare RD, Sgroi D, Ryan PD, Garber JE, Schnitt SJ. Estrogen receptor positive breast cancers in BRCA1 mutation carriers: clinical risk factors and pathologic features. *Breast Cancer Res*. 2010, 12 (1), R12
17. Zhou C, **Wang Y**, Aguirre A, Tsai T, Cohen D, Connolly J and Fujimoto J. Ex vivo imaging of human thyroid pathology using integrated optical coherence tomography (OCT) and Optical Coherence Microscopy (OCM). *J Biomed Optics*, 2010, 15(1)
18. Zhou C, Tsai T, Adler D, Lee H, Cohen D, Mondelblatt A, **Wang Y**, Connolly J, and Fujimoto J. Photothermal optical coherence tomography in ex vivo human breast tissues using gold nanoshells. *Optics letters* 2010, 35(5)
19. Dialani V, Hines N, **Wang Y** and Slanetz P. Breast schwannoma. *Case Report in Medicine*, 2011, v2011, Feb 9

20. Tamimi RM, Colditz GA, **Wang Y**, Collins LC, Hu R, Rosner B, Irie HY, Connolly JL, Schnitt SJ. Expression of IGF1R in normal breast tissue and subsequent risk of breast cancer. *Breast Cancer Res Treat.* 2011, 128(1), 243-50
21. Zerbini LF, de Vasconcellos JF, Czibere A, **Wang Y**, Pacceze JD, Gu X, Zhou JR, Libermann TA. JunD-mediated repression of GADD45alpha and gamma regulates escape from cell death in prostate cancer. *Cell Cycle*, 2011 Aug 1, 10 (15).
22. **Wang Y**, Zhu C, and Whitney K. Bilateral cribriform atypical ductal proliferation in male breast; a mimicker of female cribriform atypical ductal hyperplasia? *Histopathology*, 2011, 59 (1), 148-150
23. Lee H, Zhou C, Cohen DW, Mondelblatt AE, **Wang Y**, Aguirre AD, Shen D, Sheikine Y, Fujimoto JG and Connolly JL. Integrated Optical Coherence Tomography and Optical Coherence Microscopy Imaging of Ex Vivo Human Renal Tissues. *Journal of Urology*, 2012, 187 (2), 691-9
24. Kaplan JS, Schnitt SJ, Collins LC, **Wang Y**, Garber JE, Montgomery K, West RB, Krag K, Fettes K, Lincoln A, Tung NM. Pathologic Features and Immunophenotype of Estrogen Receptor-positive Breast Cancers in BRCA1 Mutation Carriers. *American Journal of Surgical Pathology* 2012, 36 (10), 1483-8
25. Chao SK, **Wang Y***, Verdier-Pinard P, Yang CH, Liu L, Rodriguez-Gabin A, McDaid HM, and Horwitz SB. Characterization of an Immunohistochemistry-compatible beta V tubulin antibody specific for the human isotype. ** co-first author.* *Cytoskeleton* 2012, 69, 566-76
26. Dorokhova O, Fineberg S, Koenigsberg T and **Wang Y***. Diabetic Mastopathy, a clinicopathological correlation of 32 cases. *Pathology International*, 2012, 62; 660-664 ***corresponding author**
27. **Wang Y**, Sparano JA, Fineberg S, Stead L, Sunkara J, Horwitz SB and McDaid High expression of class III beta tubulin predicts good response to neoadjuvant taxane and doxorubicin/ cyclophosphamide-based chemotherapy in estrogen receptor-negative breast cancer. *Clinical Breast Cancer*, 2013, 13(2), 103-108.
28. Yeo EJ, Cassetta L, Qian BZ, Lewkowich I, Li JF, Stefater JA 3rd, Smith AN, Wiechmann LS, **Wang Y**, Pollard J, Lang RA. Myeloid WNT7b mediates the angiogenic switch and metastasis in breast cancer. *Cancer Res.* 2014, 74(11); 2962-73.
29. Kalife, E, Lourenco A, Baird G, **Wang Y***. Clinical and Radiologic Follow-up Study for Biopsy Diagnosis of Radial Scar/Radial Sclerosing Lesion without other Atypia. *Breast J.* 2016, 22 (6): 637-644. ***corresponding author**
30. Brodsky AS, Xiong J, Yang D, Schorl C, Fenton M, Graves TA, Sikov W, Resnick M, and **Wang Y***. Identification of stromal marker ColXa1 and tumor inflating lymphocytes as putative predictive markers of stromal marker of response to neoadjuvant therapy in hormone positive/Her2 positive breast cancer. *BMC Cancer* 2016, 16:274 – 287. ***corresponding author**
31. **Wang Y**, Resnick MR, Lu S, Hui, Brodsky AS, Yang D, Yakirevich E, Wang L. Collagen type III alpha1 as a useful diagnostic immunohistochemical marker for fibroepithelial lesions of the breast. *Human Pathology* 2016, 57:176-181
32. **Wang Y**, Lu S, Graves T, Ouseph M, Resnick MR, Yakirevich E. Can Sentinel Lymph Node Biopsy Be Spared in Papillary Carcinoma of the Breast? *Clinical Breast Cancer*, 2017, 17(2): 127-236
33. Hui Y, Elco C, Heintz N, Lourenco A, Wiggins D, **Wang Y***. Diffuse dermal angiomatosis, a mimic of inflammatory breast cancer. *Breast J*, 2017 Aug, epub (PMID: 28744985),. ***corresponding author**
34. Ward RC, Donegan L, **Wang Y**, Chadashvilli T and Lourenco AP, Glomangioma of the male breast. *Breast J*, accepted. 2016

35. Loudig O, Wang T, Ye K, Lin J, **Wang Y**, Ramnauth A, Liu C, Stark A, Chitale D, Greenlee R, Multerer D, Honda S, Daida Y, Feigelson H, Glass A, Couch FJ, Tuschl T, Rohan T and Ben-dov I Optimization of cDNA library preparation for retrospective next-generation sequencing of microRNAs in Ductal Carcinoma in situ (DCIS). International Journal of Molecular Science, 2017, 18 (3), 627-47
36. Singh K, **Wang Y**, Marketkar S, Kalife ET, Steinhoff M. Is Estrogen Receptor, Progesterone Receptor and HER2 Testing Necessary on All Concurrently Sampled Ipsilateral Invasive Breast Cancers; A Retrospective Study of 246 Biopsies from 119 Patients. Human Pathology, 2017, April 17 epub
37. Hendry S, et al , Assessing Tumor-infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method From the International Immunoncology Biomarkers Working Group: Part 1: Assessing the Host Immune Response, TILs in Invasive Breast Carcinoma and Ductal Carcinoma In Situ, Metastatic Tumor Deposits and Areas for Further Research. The International Immuno-Oncology Biomarkers Working Group. Accepted by Advances in Anatomic Pathology, 2017, PMID 28777142
38. Hendry S, et al, Assessing Tumor-Infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method from the International Immuno-Oncology Biomarkers Working Group: Part 2: TILs in Melanoma, Gastrointestinal Tract Carcinomas, Non-Small Cell Lung Carcinoma and Mesothelioma, Endometrial and Ovarian Carcinomas, Squamous Cell Carcinoma of the Head and Neck, Genitourinary Carcinomas, and Primary Brain Tumors. The International Immuno-Oncology Biomarkers Working Group. Accepted by Advances in Anatomic Pathology, 2017, PMID 28777142
39. Arthur R, **Wang Y**, Ye K, Glass A, Ginsberg M, Loudig O, Rohan T. Association between lifestyle, menstrual/reproductive history, and histological factors and risk of breast cancer in women biopsied for benign breast disease. Breast Cancer Research and Treatment, accepted, 2017
40. **Wang Y**. Brodsky AS, Xiong J, Yang D, , Resnick M Stromal Clusterin Expression Predicts Therapeutic Response to Neoadjuvant Chemotherapy in Triple Negative Breast Cancer, Clinical Breast Cancer, accepted, 2017

MANUSCRIPTS SUBMITTED

1. Yao J, Chung S, **Wang Y**, Mcpherson W, Suyama K, Loudig O, Phillips G, Kitsis R, Norton L, and Hazan R. AKT3 acts as a **suppressor** of tumorigenesis by promoting apoptosis via receptor tyrosine kinase endocytosis; Submitted to EMBO J
2. Jackson CL, Hang S, Hansen K, He M, Sung J, Quddus, MR, Steinhoff MM, Xiong, M, **Wang Y**, Patel NR, Lawrence WD, Xiong J. Endometrial adenocarcinomas with significant mucinous differentiation: A characterization of intratumoral heterogeneity of KRAS Mutations in mucinous and endometrioid histologic components, Submitted to Gynecologic Oncology, 2017
3. Zavitsanos P, Wazer D, Hapel J, **Wang Y**, Singh K, Leonard K. BRCA1 mutations associated with increased risk of brain metastases in breast cancer: A 1:2 matched pair analysis. Submitted to Cancer 2017

PUBLICATION, THESIS

2000 Na^+/Ca^{2+} exchanger reduced cytotoxicity caused by calcium overload
Research adviser: Robert A Colvin, Ph.D.

ABSTRACTS

1. Wang C., Lewark, A., **Wang, Y.**, Davis, N., and Colvin, R.A. (1998) Na⁺/Ca²⁺ exchanger activity is increased in H₂O₂ treated primary rat cortical culture. Society for Neuroscience Abstracts 24: 1604
2. **Wang Y** and Colvin R. A. (1999) Characterization of a PC12 cell line overexpressing the Na⁺/Ca²⁺ exchanger NCX1 isoform. Society for Neuroscience Abstracts 25:2208
3. **Wang Y.** and Colvin, R. A. (2000) Na⁺/Ca²⁺ exchanger reduced cytotoxicity caused by calcium overload. Biophysical Society Abstracts 2000 56A
4. **Wang Y.** and Colvin, R. A. (2000) The role of Na⁺/Ca²⁺ exchanger in calcium ionophore induced cytotoxicity in PC 12 cells. FASEB J. 14 (8) A1574
5. **Wang, Y,** Pampou, S and Varticovski, L. The mechanism by which Ang1 blocks VEGF-mediated vascular permeability. Blood 96(11) 62b, 2000.
6. **Wang, Y,** and Varticovski, L (2001). Angiopiotein I (Ang1) blocks VEGF-mediated vascular permeability in a PAF independent pathway. Department of Physiology, Tufts School of Medicine Research Retreat, Woods Hole, MBL
7. Zerbini, L., **Wang, Y.** Libermann, T. Deregulated IL-6 gene expression in prostate cancer: A target for therapeutic intervention. DFHCC Symposium, 2003 Newport, RI
8. Zerbini, L, **Wang, Y,** Cho, J, Inan, M, Jones, J, Bailey, C, Joseph, M, Gu, X, Zhou, J, and Libermann, T. Transcription factor NF-κB and AP-1 as targets for prostate cancer gene therapy. Molecular Gene Therapy 7(5) S415, 2003.
9. **Wang Y,** Zerbini LF, Czebere A and Libermann TA. The non-steroid anti-inflammatory drug Sulindac Sulfide induces apoptosis and growth arrest in prostate cancer cells. USCAP 2005.
10. **Wang Y** and Fu Y. Evaluation of lymphatic and blood vessel density in thyroid tumors. 100th International Academy of Pathology (IAP), 2006.
11. **Wang Y,** Qian Q, and Kirby J. Testing of multiple induced sputa for Pneumocystis Pneumonia does not significantly increase diagnostic yield. Arch Pathol 2006.,130, 1396
12. **Wang Y,** Kirby J and Qian Q. Definition of the optimal use of JC Virus PCR testing for diagnosis of progressive multifocal leucoencephalopathy. Arch Pathol 2006., 130, 1396
13. **Wang Y,** Genega EM and Fu Y. Lymphatic vessel density does not associate with tumor grade in prostate cancer. USCAP 2007.
14. **Wang Y,** Collins L, Schnitt S, Garber J, and Tung, N. Characterization of estrogen receptor positive breast cancers in BRCA1 mutation carriers. USCAP 2008.
15. **Wang Y** and Fu, Y. Renal oncocytoma: a clinicopathological analysis of thirty-six cases. USCAP 2008.
16. **Wang Y,** Collins L, Schnitt S, Garber J, and Tung, N. Characterization of estrogen receptor positive breast cancers in BRCA1 mutation carriers (update). 31st Annual San Antonio Breast Cancer Symposium 2008.

17. Zhou C, Aguirre AD, **Wang Y**, Bryan B, Tsai T, Connolly JL, and Fujimoto JG. Ex vivo imaging of human pathologies with integrated optical coherence tomography (OCT) and optical coherence microscopy (OCM). In Photonics West, SPIE, 2009.
18. Comander AH, Gallagher BM, Krag K, **Wang Y**, Li H, Gelman R, Collins LC, Schnitt SJ, Garber JE, Tung N. Determination of factors predicting for estrogen receptor positive (ER+) breast cancers in *BRCA1* mutation carriers ASCO annual meeting 2009.
19. Genega EM, Ghebremichael M, Najarian R, Fu Y, **Wang Y**, Grisanzio C, Signoretti S. CAIX expression in renal neoplasms: correlation with tumor type and grade. USCAP 2009.
20. **Wang Y**, Genega E, Signoretti S and Fu Y. Immunohistochemical analysis of oncocytic renal tumors. USCAP 2009.
21. **Wang Y**, Connolly J, Hu R, Baer H, Colditz G, Schnitt S, Collins, L and Tamimi R. Expression of insulin-like growth factor-1 receptor (IGF1-R) in normal breast tissue and breast cancer risk: results from the Nurses' Health Study. USCAP 2009.
22. Kaplan J, Schnitt S, Collins L, **Wang Y**, Garber J and Tung N. Estrogen receptor (ER)-positive breast cancers in *BRCA1* mutation carriers: mutation-related or sporadic? 32st Annual San Antonio Breast Cancer Symposium 2009.
23. Kaplan J, Schnitt S, Collins L, **Wang Y**, Garber J, Montgomery K, West R, van de Rijn M and Tung N. Histologic and immunophenotypic comparison of estrogen receptor (ER)-positive breast cancers in *BRCA1* mutation carriers and sporadic ER-positive breast cancers: a case-control study, USCAP 2010.
24. Hilson J, **Wang Y**, Connolly J, Schnitt S, Collins L and Tamimi R. Estrogen receptor-beta expression in normal breast tissue in relation to benign breast disease category and breast cancer risk: results from the Nurses' Health Study. USCAP 2010.
25. **Wang Y**, Sparano J, Sunkara J, Horwitz S, and McDaid H. Analysis of class III beta tubulin by molecular subtype in breast cancer -- a pilot study, USCAP 2011.
26. Cole A and **Wang Y**, Granular cell tumor of the breast: a clinicopathologic study of 15 cases. CAP'11 Annual Meeting, 2011.
27. Dorokhova O, Fineberg S, Koenigsberg T and **Wang Y**. Diabetic Mastopathy, a Clinicopathological Correlation of 32 Cases. USCAP 2012
28. Kalife E, Lourenco A, Resnick M, Mainiero M, **Wang Y**. Clinical and Radiologic Follow-up Study for Biopsy Diagnosis of Radial Scar/Radial Sclerosing Lesion without other Atypia. USCAP 2013
29. Marketkar, S, **Wang Y** and Amin A. Malignant mesothelioma of the tunica vaginalis testis: Case report and diagnostic challenges. CAP'14 Annual Meeting, 2014
30. Li J, Lu S, Yakirevich E and **Wang Y**. Decreased claudin 7 expression is associated with the development of mammary Paget's disease. CAP'14 Annual Meeting, 2014
31. Wang H, Lourenco A and **Wang Y**. Rare Adenoid Cystic Carcinoma Of The Breast Mimicking Infiltrating Syringomous Tumor Of The Nipple And Low Grade Adenosquamous Carcinoma: A Case Report. CAP'15 Annual Meeting, 2015
32. Wang H, **Wang Y**, and Amin A. Mature retroperitoneal cystic teratoma associated with left adrenal gland in a 61 year old male: A case report. CAP'15 Annual Meeting, 2015

33. Dibble E, Li J, **Wang Y** and Lourenco A. Sensitivity of Mammogram, Ultrasound, and MRI for detecting malignancy in pathologically-proven Paget's disease of the breast. SBI/ACR Breast Imaging Symposium. April, 2016 Los Angeles.
34. Ouseph M, Brodyski A, Xiong J, Resnick M, and **Wang Y**. Stromal ColX α 1 and Tumor-Infiltrating Lymphocytes Predicts Response to Neoadjuvant Therapy in HER2-Positive Breast Cancer Depending on Their Estrogen Receptor Status. USCAP 2016
35. Marketkar S, Singh K, Jackson CL, Hart J, Resnick M, and **Wang Y**. Impact of 2013 ASCO/CAP Guideline Recommendations on HER2 FISH Testing in Breast Cancer, USCAP 2016
36. Zhao C, Yakirevich E; Lombardo K, Gnepp DR, and **Wang Y**. The utility of GATA3, GCDFP-15 Mammaglobin, SOX10, and ER in Differential Diagnosis of Salivary Tumors. USCAP 2016
37. Wang L, **Wang Y**, Zhao S, Zhang Y, Zhang Z. Direct IHC using polyHRP labeled Transtumab (Herceptin) – A potential new companion diagnostic test for Heceptin treatment. USCAP 2016
38. He X, Wood S, Lourenco A, Yakirevich E, Wang Y. Lupus Gastrointestinal Vasculitis Involving Small and Medium Vessels in a Young Woman Presenting with Multiple Intestinal Perforations. CAP'16 Annual Meeting, 2016
39. He X, Wood S, **Wang Y**, Matoso A, Hart J. Gastric Ewing Sarcoma/Primitive Neuroectodermal Tumor (PNET): A case report of an unusual primary site. CAP'16 Annual Meeting, 2016
40. Patil PA, Lourenco A, Aswad B, **Wang Y**. Infiltrating Ductal Carcinoma With Comedo-necrosis And Pseudo-myoepithelial Like Layer, Mimicking High-grade Ductal Carcinoma In Situ (DCIS) - A Case Report. CAP'16 Annual Meeting, 2016
41. Wang H, Yu G, Lombardo K, Yang D, **Wang Y**. Immunohistochemistry Marker Comparison in Primary Breast Cancers with their first metastasis to Liver and Bone. CAP'16 Annual Meeting, 2016
42. Cobb C, Lazarus E, **Wang Y**, Lourenco AP. Will You Pass the Test: Radiologic and Pathologic Spectrum of Architectural Distortion on Mammography and Digital Breast Tomosynthesis. 102th Scientific assembly and annual meeting, Radiological Society of North America, Chicago, 2016
43. Singer, TM; Lourenco AP, Baird, GL; Wang H; **Wang Y**, MD; Mainiero MB. Lobular Carcinomas in the era of digital breast tomosynthesis: Are imaging findings changing? 102th Scientific assembly and annual meeting, Radiological Society of North America, Chicago, 2016
44. Hui Y, Lombardo K, Resnick M, **Wang Y**. Metastatic breast carcinoma with signet ring feature verses gastrointestinal signet ring cell tumor: assessment of immunohistochemical markers, accepted by USCAP 2017
45. Wang H, Hui Y, Resnick M, **Wang Y**. Discordant Her2 immunohistochemical expression and gene amplification by in situ hybridization in ductal carcinoma in situ, accepted by USCAP 2017
46. He X, Kalife ET, Ehdaivand S, **Wang Y**, Sung J and Singh K. Breast Cancer Histologic Grade and Histologic Subtype Impact Recurrence Score; Retrospective Review of 863 Oncotype Dx Results, accepted by USCAP 2017
47. Singh K, Paquette C, Kalif ET, **Wang Y**, Mangray S, Quddus R, Steinhoff MM. Inter-Observer Variability in Diagnosing Lobular Carcinoma-in-Situ Subtypes; Evaluating Reproducibility of Contemporary Criteria, accepted by USCAP 2017
48. Xiong J, **Wang Y**, Steinhoff MM, Sung J, Quddus, RM, Jolly GA, Dwayne W and Hansen K. Squamous morules: Re-examination of a well-known entitle –An ultrastructural and immunohistochemistry study, accepted by USCAP 2017

49. Jimoh N, Dibble E, **Wang Y** and Lourenco A. Beyond gynecomastia: Spectrum of male breast disease, submitted to SBI/ACR Breast Imaging Symposium 2017
50. Dibble E, Jimoh N, **Wang Y** and Lourenco A. Will you pass the test? Radiology-pathology correlation of infectious, submitted to SBI/ACR Breast Imaging Symposium 2017
51. Wang H, and Wang Y, Calcium Oxylate in breast core needle biopsy, accepted by CAP'17 Annual meeting

INVITED TALKS AND PLATFORM PRESENTATIONS

Speaker	Grand round, Department of Biomedical Science, College of Arts and Sciences, Ohio University, 1999 "Characterization of a PC12 cell line overexpressing the Na ⁺ /Ca ²⁺ exchanger NCX1 isoforms"
Speaker	Department of Physiology Seminar Series, Tufts University, 2001 "Vascular Endothelial Growth Factor (VEGF) and Angiopoietin I (Ang1) in Vascular Permeability"
Speaker	Laboratory Round, Department of Biomedical Research, St. Elizabeth's Medical Center, Tufts University, 2001 "PI 3-kinase in protein-tyrosine kinase-mediated signal transduction in cell growth and vesicular trafficking"
Speaker	BIDMC Genomic Center/ Harvard Medical School, 2003 "Transcription Factors NF- κ b as Targets for Cancer Gene Therapy"
Speaker	Surgical Pathology Conference, Department of Pathology, Beth Israel Deaconess Medical Center, 2004 "Proteomics"
Speaker	Surgical Pathology Conference, Department of Pathology, Beth Israel Deaconess Medical Center, 2005 "Thyroid Carcinoma Update"
Speaker	Surgical Pathology Conference, Department of Pathology, Beth Israel Deaconess Medical Center, 2006 "Tumor Lymphoangiogenesis"
Finalist	Annual Beth Israel Deaconess Medical Center Research Day presentation, 2007 "Pathological Characterization of BRCA1 mutation associated breast cancers"
Speaker	Fifth Annual Dana-Farber/Harvard Cancer Center (DF/HCC) Breast Symposium, 2008 "Characterization of estrogen receptor positive breast cancers in BRCA1 mutation carrier" - Y Wang, L Collins, S Schnitt, J Garber and N Tung
Invited Speaker	School of Medicine, Shandong University, China, 2009 "Pursuing Medical Career in the United States"
Lecturer	Albert Einstein College of Medicine, 2009 – 2012 Breast pathology lecture, Reproductive and Endocrine course (second year medical student course)
Lecturer	Albert Einstein College of Medicine Pathology Residency Program, 2009

	“Radiology-Pathology correlation in Breast Core Biopsy Interpretation”
Lecturer	Albert Einstein College of Medicine Pathology Residency Program, 2010 “Differential Diagnosis of Rare Breast Lesions”
Invited Speaker	Department of Pathology and Laboratory Medicine, Women and Infant Hospital/ Warren Alpert Medical School of Brown University, Rhode Island; 2011 “HER2/neu heterogeneity”
Lecturer	Brown Medical School Pathology Residency Program, 2012 - “Interesting Cases of Benign Breast Disease” - “Interesting Cases of Malignant Breast Disease”
Speaker	Grand round, Department of Pathology and Laboratory Medicine, Rhode Island Hospital/Warren Alpert Medical School of Brown University 2013 “Practical Approach to Gynecological Intraoperative Assessment”
Lecturer	Brown Medical School Pathology Residency Program, 2013 - “Introduction to Breast Grossing” - “Papillary Lesions of the Breast”
Course Faculty	International Centre for Genetic Engineering and Biotechnology (ICGEB)/World Health Organization (WHO) “Advances in Prostate and Breast Cancer Research” Course Cape Town, South Africa. 2014 - “Breast cancer epidemiology and risk factors” - “Breast cancer pathology and clinical implication”
Lecturer	Brown Medical School Pathology Residency Program, 2014 - “Introduction to Breast Grossing” - “Fibroepithelial Lesions of the Breast”
Speaker	Grand round, Department of Pathology and Laboratory Medicine, Rhode Island Hospital/Warren Alpert Medical School of Brown University, 2015 “Tumor Infiltrating Lymphocytes”
Invited Speaker	Department of Pathology and Laboratory Medicine, Women and Infant Hospital/ Warren Alpert Medical School of Brown University, 2015 “Update on Tumor Infiltrating Lymphocytes”
Lecturer	Brown Medical School Pathology Residency Program, 2015 - “Introduction to Breast Grossing” - “Ductal Carcinoma in Situ, current update”
Invited Speaker	21 st Congress of Chinese Society of Pathology and 5 th Annual Meeting of Chinese Pathologists, Kunming, China, 2015 - Slide Seminar “A Rare Adenoid Cystic Carcinoma of the Breast” - Workshop Breast Pathology Session “ Tumor infiltrating Lymphocytes in Breast Cancer and its Clinical implication”
Lecturer	Brown Medical School Pathology Residency Program, 2016 - “Introduction to Breast Grossing” - “Diagnostic Challenges in Breast Needle Core Biopsy”
Lecturer	Warren Alpert Medical School of Brown University, 2016 Endocrine lecture, BIOL 3643 IMS I: Histology